Search for Clinical Trial Results
Pheochromocytoma - 29 Studies Found
Status | Study |
Available |
Study Name: Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma Condition:
Date: 2011-06-13 Interventions: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG) Therapeutic 131I-MIBG will be synthesized at Nuclear Di |
Completed |
Study Name: A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors Condition:
Date: 2011-08-08 Interventions: Radiation: 131I-MIBG Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rock |
Completed |
Study Name: Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Condition:
Date: 2007-04-09 Interventions: Drug: Ultratrace Iobenguane (MIBG) I 131 Phase I: Dose escalation protocol Phase II: Treatment schedule |
Active, not recruiting |
Study Name: A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Condition:
Date: 2009-04-01 Interventions: Radiation: Ultratrace® Iobenguane I131 Each subject will be administered 3 mCi to 6 mCi Ultratrace& |
Available |
Study Name: Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Condition:
Date: 2016-11-08 Interventions: Drug: Ultratrace Iobenguane I131 Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 who |
Active, not recruiting |
Study Name: Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Condition:
Date: 2013-10-19 Interventions: Drug: Axitinib (AG-013736) Axitinib will be given as self-administered oral doses at the initial level o |
Active, not recruiting |
Study Name: Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation Condition:
Date: 2014-06-04 Interventions: Other: PET-CT |
Withdrawn |
Study Name: Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Condition:
Date: 2013-09-10 Interventions:
|
Not yet recruiting |
Study Name: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Condition:
|
Completed |
Study Name: Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma Condition:
|